Anbio Biotechnology Reports H1 2025 Financials
Ticker: NNNN · Form: 6-K · Filed: Dec 30, 2025 · CIK: 1982708
| Field | Detail |
|---|---|
| Company | Anbio Biotechnology (NNNN) |
| Form Type | 6-K |
| Filed Date | Dec 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 6-k, biotechnology
TL;DR
Anbio Biotech dropped its H1 2025 unaudited financials on Dec 30th.
AI Summary
Anbio Biotechnology, a Cayman Islands exempted company, announced its unaudited financial results for the six months ended June 30, 2025, via a press release on December 30, 2025. The company is headquartered in Frankfurt am Main, Germany.
Why It Matters
This filing provides investors with unaudited financial performance data for Anbio Biotechnology for the first half of 2025, allowing for an assessment of the company's recent financial health.
Risk Assessment
Risk Level: low — This is a routine financial results announcement (6-K filing) and does not contain significant new risks.
Key Players & Entities
- Anbio Biotechnology (company) — Filer of the report and subject of the financial results
- December 30, 2025 (date) — Date of the press release and filing
- June 30, 2025 (date) — End date for the reported financial period
- Frankfurt am Main, Germany (location) — Company's principal executive offices
FAQ
What type of company is Anbio Biotechnology?
Anbio Biotechnology is a Cayman Islands exempted company operating in the In Vitro & In Vivo Diagnostic Substances industry.
When were the financial results reported?
The unaudited financial results for the six months ended June 30, 2025, were announced on December 30, 2025.
Where is Anbio Biotechnology's principal executive office located?
Anbio Biotechnology's principal executive offices are located at Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt am Main, Germany.
What is the SEC file number for Anbio Biotechnology?
The SEC file number for Anbio Biotechnology is 001-42526.
Does Anbio Biotechnology file annual reports under Form 20-F?
Yes, Anbio Biotechnology indicates it files annual reports under cover of Form 20-F.
Filing Stats: 204 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2025-12-30 16:30:01
Filing Documents
- ea0271224-6k_anbio.htm (6-K) — 9KB
- ea027122401ex99-1_anbio.htm (EX-99.1) — 43KB
- 0001213900-25-126654.txt ( ) — 52KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Anbio Biotechnology Date: December 30, 2025 By: /s/ Michael Lau Name: Michael Lau Title: Chief Executive Officer 2